Be Bio is pioneering Engineered B cell Medicines (BCMs) to dramatically improve the lives of patients who are living with genetic disease, cancer, and other serious conditions.
The B cell is a powerful cell that produces thousands of proteins per cell per second at constant levels over decades. Precision engineering can now be used to develop BCMs that have the potential to be durable, allogeneic, re-dosable, and administered without preconditioning. The promise of BCMs could transform therapeutic biologics across protein classes, patient populations, and therapeutic areas.
Founded by Longwood Fund and B cell engineering pioneers David Rawlings, MD and Richard James, PhD, Be Bio is re-imagining medicine based on the power of B cell biology.
